H.C. Wainwright assumed coverage of Xeris Biopharma (XERS) with a Buy rating and $10 price target The firm believes the commercial potential of the company’s commercial portfolio remains “meaningfully underappreciated.” The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: